其他技能

Deprecated alias — use `/woz settings`.

中文简介正在准备中。当前显示原文说明。

Deprecated alias — use `/woz benchmark`.

中文简介正在准备中。当前显示原文说明。

Deprecated alias — use `/woz login`.

中文简介正在准备中。当前显示原文说明。

Deprecated alias — use `/woz update`.

中文简介正在准备中。当前显示原文说明。

Deprecated alias — use `/woz-feedback` (bug reports).

中文简介正在准备中。当前显示原文说明。

Find current job postings on employer career pages and job boards. Use when the user asks who's hiring, seeks remote or local jobs, or wants openings matched to their role, skills, experience, or salary preferences.

中文简介正在准备中。当前显示原文说明。

Monitor competitor pricing, features, changelogs, dashboards, and product changes with Firecrawl. Use for recurring competitive intelligence, pricing tier extraction, feature change tracking, or structured competitor alerts.

中文简介正在准备中。当前显示原文说明。

Med-adapted earnings preview: consensus estimates, historical surprises, guidance sensitivities, and the FDA-catalyst overlay (PDUFA/AdCom/trial readouts near the print) for biotech/pharma names.

中文简介正在准备中。当前显示原文说明。

Valuation methods analysis, DCF inputs, comparable multiples, P/E ratio, EV/EBITDA, price to book, valuation assumptions, relative valuation, intrinsic value, fair value estimate

中文简介正在准备中。当前显示原文说明。

Risk analysis, regulatory risk assessment, competitive risk, macro risk, technology risk, litigation risk, financial risk assessment, enterprise risk, operational risk, geopolitical risk exposure

中文简介正在准备中。当前显示原文说明。

Secular technology trends, technology adoption cycle, disruption risk, AI impact analysis, digital transformation, industry 4.0 trends, technology moat, innovation trajectory, R&D effectiveness, tech competitive positioning

中文简介正在准备中。当前显示原文说明。

Recent quarter performance analysis, quarterly earnings review, last quarter results, quarterly financial performance, analyze recent quarter, Q4 earnings, quarterly revenue breakdown, EPS this quarter, margin analysis recent quarter, sequential growth, quarterly performance review

中文简介正在准备中。当前显示原文说明。

Med peer benchmarking: select actual biotech/pharma peers via the med universe (drug/indication overlap where possible) and compare med-relevant metrics — pipeline depth, catalyst density, cash position, margins, valuation multiples.

中文简介正在准备中。当前显示原文说明。

Medicines pipeline analysis over structured universes: Phase I-III assets with probability-of-success discipline (unadjusted peak x POS = modeled value; POS changes logged with reasons), trial status-diff tracking, and mechanism/competitor mapping via drug-knowledge lookups.

中文简介正在准备中。当前显示原文说明。

Med-adapted recent-quarter review: last print financials, pipeline-milestone awareness, and FDA-event context — reads the quarter through the med lens (milestones moved, runway, regulatory updates) rather than generic financials alone.

中文简介正在准备中。当前显示原文说明。

Competitive landscape analysis, competitor comparison, peer positioning, market share dynamics, competitive moat assessment, Porter five forces, industry competition, competitive advantage analysis, market positioning, strategic group mapping, compare competitors

中文简介正在准备中。当前显示原文说明。

Patient-flow market sizing for med products — prevalence → diagnosed → interested → affordable → covered → treated → persistent, priced as price × duration per cohort, with capacity constraints, named historical analog anchoring, and always bull/base/bear named-driver grids. Use to size a therapy area or product market before any valuation or share work.

中文简介正在准备中。当前显示原文说明。

Post-event analyst note (conferences, KOL events, site visits) with the professional note anatomy — headline verdict, per-stock takeaways with model numbers, KOL distillation, cross-trial comparison lattices, modeled deltas vs consensus (peak × POS), three what's-changed vectors, risk bullets, and materiality-rated conflicting views. Use after any med event to convert the event into actionable takeaways.

中文简介正在准备中。当前显示原文说明。

Device-track catalyst analysis: 510(k), PMA, and De Novo decision events, CMS coverage and NTAP milestones, recalls and watch actions as risk signals, and post-market surveillance obligations — dated, verified, and sized per event for any medtech ticker or watchlist.

中文简介正在准备中。当前显示原文说明。

CDER-track catalyst analysis for medicines: PDUFA target dates, AdCom votes, sNDA/sBLA label expansions, biosimilar interchangeability and 180-day exclusivity, Orange Book state, and CRL remediation timelines — enumerated, verified, and sized per event for any biotech/pharma ticker or watchlist.

中文简介正在准备中。当前显示原文说明。

Med-sector overview across med.medicines_biotech and med.medical_devices with med trends, catalysts, FDA-decision context, and a cross-sector ripple map (quantified sign/magnitude per name). Use to frame any biotech/pharma/device analysis before diving into a single name.

中文简介正在准备中。当前显示原文说明。

Financial ratio analysis, profitability ratios ROE ROA ROIC, liquidity ratios current quick cash, leverage ratios debt-to-equity interest coverage, efficiency ratios asset turnover inventory turnover DSO, valuation ratios PE PB EV/EBITDA, cross-company ratio comparison, DuPont analysis

中文简介正在准备中。当前显示原文说明。

Technical execution timing, entry exit signals, price action analysis, volume profile, market structure, support resistance levels, trend identification, Wyckoff method, auction market theory, trade management timing, position entry exit optimization

中文简介正在准备中。当前显示原文说明。

Dividend Discount Model, DDM valuation, multi-stage dividend model, Gordon Growth Model, dividend growth valuation, mature company valuation, income stock valuation, dividend yield analysis

中文简介正在准备中。当前显示原文说明。